Nanoparticle targeting to inflamed tissues of the gastrointestinal tract

Current Drug Delivery

Volumn 10, Issue 1, 2013, Pages 9-17

  Moulari, Brice ^a   Beduneau, Arnaud ^a   Pellequer, Yann ^a   Lamprecht, Alf ^a,b  

^a France   (France)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Drug targeting; Gastric ulcer; Inflamed barriers; Inflammatory bowel disease; Liposomes; Nanoparticles

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; NANOCARRIER; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TACROLIMUS;

ARTICLE; COLITIS; COLLOID; CROHN DISEASE; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENTERITIS; HUMAN; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STOMACH ULCER;

ANIMALS; DRUG CARRIERS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; NANOPARTICLES; STOMACH ULCER;

EID: 84875297969     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201811310010004     Document Type: Article

References (77)

1. Baumgart, D.C., Sandborn, W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007, 369, 1641-1657.
2. Fiocchi, C. Inflammatory bowel disease: current concepts of patho-genesis and implications for therapy. Minerva Gastroenterol. Die-tol., 2002, 48, 215-226.
3. Peterson, W.L. Helicobacter pylori and peptic ulcer disease. N. Engl. J. Med., 1991, 324, 1043-1048.
4. Konturek, S.J. Role of epidermal growth factor in gastroprotection and ulcer healing. Scand. J. Gatroenterol., 1988, 23, 129-133.
5. Sener-Muratoglu, G.; Paskaloglu, K.; Arbak, S., Hurdag, C., Aya-noglu-Dulger, G. Protective effect of famotidine, omeprazole, and melatonin against acetylsalicylic acid induced gastric damage in rats. Dig. Dis. Sci., 2001, 46, 318-330.
6. Bennett, N.T., Schultz, G.S. Growth factors and wound healing: part II. Role in normal and chronic wound healing. Am. J. Surg., 1993, 166, 74-81.
7. Correa, P. Helicobacter pylori and gastric carcinogenesis. Am. J. Surg. Pathol., 1995, 19, 37-43.
8. Bresci, G., Parisi, G., Bertoni, M., Capria, A. Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up. Dig. Liver Dis., 2002, 34, 419-423.
9. Farup, P.G., Hinterleitner, T.A., Lukás, M., Hébuterne, X., Rachmilewitz, D., Campieri, M., Meier, R., Keller, R., Rathbone, B., Oddsson, E. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcera-tive colitis. Inflamm. Bowel Dis., 2001, 7, 237-242.
10. Moulari, B., Pertuit, D., Pellequer, Y., Lamprecht, A. Targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials, 2008, 29, 4554-4560.
11. Makhlof, A., Tozuka, Y., Takeuchi, H. pH-sensitive nanoparticles for colon-specific drug delivery in experimentally induced colitis rat model. Eur. J. Pharm. Biopharm., 2009, 72, 1-8.
12. G. Liposomes as drug carriers. Ed., John Wiley and Sons, New York, 1988.
13. Müller, R. Carriers for controlled drug delivery and targeting, CRC Press, Bocca Raton, 1991.
14. A. Pharmaceutical particulate carriers. Ed., Marcel Dek-ker, New York, 1993.
15. Alonso, M.J. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother., 2004, 58, 168-172.
16. Reis, C.P., Neufeld, R.J., Ribeiro, A.J., Veiga, F. Nanoencapsula-tion II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine, 2006, 2, 53-65.
17. Torchilin, V.P. Multifoncional nanocarriers. Adv. Drug Deliv. Rev., 2006, 58, 1532-1555.
18. Koziara, J.M., Whisman, T.R., Tseng, M.T., Mumper, R.J. In vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release, 2006, 112, 312-319.
19. Jeon, S.I., Lee, J.H., Andrade, J.D., De Gennes, P.G. Protein surface interactions in the presence of polyethylene oxide. I. simplified theory. J. Colloid Interface Sci., 1991, 142, 149-158.
20. Storm, G., Belliot, T., Daemen, D., Lasic, D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phago-cytic system. Adv. Drug Deliv. Rev., 1995, 17, 31-48.
21. Brigger, I., Dubernet, C., Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54, 631-651.
22. Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparti-cles. Mol. Pharm., 2008, 5, 505-515.
23. Haley, B., Frenkel, E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol., 2008, 26, 57-64.
24. Sakhalkar, H.S., Hanes, J., Fu, J., Benavides, U., Malgor, R., Bor-ruso, C.L., Kohn, L.D., Kurjiaka, D.T., Goetz, D.J. Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J., 2005, 19, 792-794.
25. Hartmann, G., Bidlingmaier, C., Siegmund, B., Albrich, S., Schulze, J., Tschoep, K., Elger, A., Lehr, H.A., Endres, S. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther., 2000, 292, 22-30.
26. Klein, S., Stein, J., Dressman, J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in vitro release model. J. Pharm. Pharmacol., 2005, 57, 709-719.
27. Rodriguez, M., Antunez, J.A., Taboada, C., Seijo, B., Torres, D. Colon-specific delivery of budesonide from microencapsulated cel-lulosic cores: evaluation of the efficacy against colonic inflammation in rats; J. Pharm. Pharmacol., 2001, 53, 1207-1215.
28. Lamprecht, A., Yamamoto, H., Takeuchi, H., Kawashima, Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther., 2005, 325, 196-202.
29. Matsumura, Y., Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor tropic accumulation of proteins and antitumor agent SMANCS. Cancer Res., 1986, 46, 6387-6392.
30. Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem., 2010, 21, 797-802.
31. Hobbs, S.K., Monsky, W.L., Yuan, F., Roberts, W.G., Griffith, L., Torchilin, V.P., Jain, R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci., 1998, 95, 4607-4612.
32. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berck, D.A., Torchilin, V.P., Jain, R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res., 1995, 55, 3752-3756.
33. Seymour, L., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., Duncan, R. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer, 1995, 31A, 766-770.
34. Rawlins, M. Clinical leadership at NICE. Lancet, 2008, 372, 601.
35. Maeda, H., Bharate, G.Y., Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm., 2009, 71, 409-419.
36. Dianzani, C., Cavalli, R., Zara, G.P., Gallicchio, M., Lombardi, G., Gasco, M.R., Panzanelli, P., Fantozzi, R. Cholesteryl butyrate sol-ide lipid nanoparticles inhibit adhesion of human neutrophils to en-dothelial cells. Br. J. Pharmacol., 2006, 148, 648-656.
37. Pellizzaro, C., Coradini, D., Morel, S., Ugazio, E., Gasco, M.R., Daidone, M.G. Cholestery butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery. Anticancer Res., 1999, 19, 3921-3926.
38. Oyen, W.J.G., Boerman, O.C., Dams, E.T.M., Storm, G., Van Bloois, L., Koenders, E.B. Scintigraphic evaluation of experimental colitis in rabbits. J. Nucl. Med., 1997, 38, 1596-1600.
39. Dams, E.T.M., Oyen, W.J.G., Boerman, O.C., Storm, G., Laver-man, P., Koeders, E.B. Technetium-99m-labeled liposomes to image experimental colitis in rabbits: comparison with Technetium-99m-HMPAO-granulocytes and Technetium-99m-HYNIC-IgG. J. Nucl. Med., 1998, 39, 2172-2176.
40. Awasthi, V.D., Goins, B., Klipper, R., Phillips, W.T. Accumulation of PEG-liposomes in the inflamed colon of rats: potential for therapeutic and diagnostic targeting of inflammatory bowel diseases. J. Drug Target, 2002, 10, 419-427.
41. Pober, J.S., Cotran, R.S. Cytokines and endothelial cell biology. Physiol. Rev., 1990, 70, 427-451.
42. Sakhalkar, H.S., Dalal, M.K., Salem, A.K., Ansari, R., Fu, J., Ki-ani, M.F. Leucocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl. Acad. Sci., 2003, 100, 15895-15900.
43. Sakhalkar, H.S., Hanes, J., Fu, J., Benavides, U., Malgor, R., Bor-ruso, C.L., Kohn, L.D., Kurjiaka, D.T., Goetz, D.J. Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J., 2005, 19, 792-794.
44. Nakase, H., Okazaki, K., Tabata, Y., Uose, S., Ohana, M., Uchida, K., Matsushima, Y., Kawanami, C., Oshima, C., Ikada, Y., Chiba, T. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther., 2000, 292, 15-21.
45. Stein, J., Ries, J., Barret, K.E. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am. J. Physiol., 1998, 274, 203-209.
46. Lamprecht, A., Schäfer, U., Lehr, C.M. Size dependent targeting of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res., 2001, 18, 788-793.
47. Lamprecht, A., Ubrich, N., Yamamoto, H., Schäfer, U., Takeuchi, H., Lehr, C.M., Kawashima, Y. Biodegradable nanoparticles for the targeted drug delivery in the treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther., 2001, 299, 775-781.
48. Finn, W.F. FK506 nephrotoxicity. Renal Failure, 1999, 21, 319-329.
49. Meissner, Y., Pellequer, Y., Lamprecht, A. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int. J. Pharm., 2006, 316, 138-143.
50. Pertuit, D., Moulari, B., Betz, T., Nadaradjane, A., Neumann, D., Ismaili, L., Refouvelet, B., Pellequer, Y., Lamprecht, A. 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J. Control. Release, 2007, 123, 211-218.
51. Jubeh, T.T., Barenholz, Y., Rubinstein, A. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm. Res., 2004, 21, 447-453.
52. D'argenio, G., Calvani, M., Petillo, O., Margarucci, S., Rienzo, M., Torpedine, A., Mazzone G., Sorrentini, I., Caporaso, N., Peluso, G. Experimental colitis: decreased Octn2 and Atb0+ expression in rat colonocytes induces carnitine depletion that is reversible by car-nitine-loaded liposomes. FASEB J., 2006, 20, 2544-2546.
53. Gao, D., Wagner, A.H., Fankhaenel, S., Stojanovic, T., Schweyer, S., Panzner, S., Hecker, M. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulfonic acid induced rat colitis. Gut, 2005, 54, 70-77.
54. Lin, Y-H., Chang, C-H., Wu, Y-S., Hsu, Y-M., Chiou, S-F., Chen, Y-J. Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti Helicobacter pylori therapy. Biomateri-als, 2009, 30, 3332-3342.
55. Hassani, S., Pellequer, Y., Lamprecht, A. Selective adhesion of nanoparticles to inflamed tissue in gastric ulcers. Pharm. Res., 2009, 26, 1149-1154.
56. Lamprecht, A. Selective nanoparticle adhesion can enhance colitis therapy. Nat. Rev. Gastroenterol. Hepatol., 2010, 7, 311-312.
57. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47, 65-81.
58. Kaul, G., Amiji, M. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J. Drug Target, 2004, 12, 585-591.
59. Yamada, T., Iwasaki, Y., Tada, H., Iwabuki, H., Chuah, M.K., Vanden-Driessche, T., Fukuda, H., Kondo, A., Ueda, M., Seno, M., Tanizawa, K., Kuroda, S. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat. Biotechnol., 2003, 21, 885-890.
60. Gulyaev, A.E., Gelperina, S.E., Skidan, I.N., Antropov, A.S., Kivman, G.Y., Kreuter, J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res., 1999, 16, 1564-1569.
61. Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R., Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug devices. J. Control. Release, 2001, 70, 1-20.
62. Torchilin, V.P. Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsul., 1998, 15, 1-19.
63. Moghimi, S.M., Szebeni, J. Stealth liposomes and long irculating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42, 463-478.
64. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J. Control. Release, 2000, 65, 271-284.
65. Torchilin, V.P. How do polymers prolong circulation times of liposomes? J. Liposome Res., 1996, 6, 99-116.
66. Davis, M.E., Chen, Z., Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer, Nat. Rev. Drug Discov., 2008, 7, 771-782.
67. Matsumoto, K., Yamamoto, T., Kamata, R., Maeda, H. Pathogene-sis of serratial infection: activation of the Hageman facto-perkallikerin cascade by serratial protease. J. Biochem., 1984, 96, 739-749.
68. Kamata, R., Yamamoto, T., Matsumoto, K., Maeda, H. A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs. Infect. Immun., 1985, 48, 747-753.
69. Molla, A., Yamaoto, T., Akaike, T., Miyashim, S., Maeda, H. Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J. Biol. Chem., 1989, 264, 10589-10594.
70. Maruo, K., Akaike, T., Inada, Y., Ohkubo, I., Ono, T., Maeda, H. Effect of microbial and mite proteases on low and high molecular weight kininogens. J. Biol. Chem., 1993, 268, 17711-17715.
71. Tanaka, S., Akaike, T., Wu, J., Fang, J., Sawa, T., Ogawa, M., Beppu, T., Maeda, H. Modulation of tumor selective vascular blood flow and extravasation by the stable prostaglandin I2 analogue beraprost sodium. J. Drug Target, 2003, 11, 45-52.
72. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science, 1983, 219, 983-985.
73. Hori, K., Suzuki, M., Tande, S. Fluctuation in tumor blood flow and effect of angiotensin induced hypertension. Jpn. J. Cancer Res., 1991, 82, 1309-1316.
74. Dvorak, H.F., Nagy, J.A., Feng, D., Brown, L.F., Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogene-sis. Curr. Top. Microbiol. Immunol., 1999, 237, 97-132.
75. Boerman, O.C., Laverman, P., Oyen, W.J.G., Corstens, F.H.M., Storm, G. Radiolabeled liposomes for scintigraphic imaging. Prog. Lipid Res., 2000, 39, 461-475.
76. Caride, V.J. Technical and biological considerations on the use of radiolabeled liposomes for diagnostic imaging. Int. J. Appl. In-strum., 1990, 17, 35-39.
77. Laverman, P., Boerman, O.C., Oyen, W.J.G., Dams, E.T.M., Storm, G., Corstens, F.H.M. Liposomes for scintigraphic detection of infection and inflammation. Adv. Drug Deliv. Rev., 1999, 37, 225-235.